Automated online monitoring & control to improve processes and decision making in cell and gene therapy manufacturing

The project aims to develop an automated, self-contained bioreactor with continuous monitoring of critical process parameters to enhance scalability and quality in cell and gene therapy manufacturing.

Subsidie
€ 3.617.783
2022

Projectdetails

Problem

Cell and gene therapies (CGT) represent a breakthrough in the treatment of a wide range of conditions. However, limited global manufacturing capacity owing to a lack of scalability prevents CGT from becoming widely available to patients. Therapies are prepared individually at central facilities in a series of complex open manual steps.

Variability is high, and a uniform manufacturing process is lacking. Automated, standardized, quality-controlled, and decentralized processes are urgently needed to scale out CGT manufacturing, bring down costs, and enable treatment for millions of patients. True automation requires an understanding of what are known as critical process parameters (CPPs). Currently, manufacturing of cell therapies is carried out over several days, with limited access to knowledge of CPPs, often obtained through intrusive sampling methods.

Innovation

We aim to enable in-line continuous monitoring of key cell culture parameters during therapy manufacturing. To do this, we will create a self-contained instrument that connects miniaturized biosensor technologies to a novel bioreactor to allow automation of the entire cell therapy manufacturing process in a closed system.

The device will accommodate a disposable, single-use sampling unit that will ultimately be adaptable to any bioreactor. Our platform will carry out continuous, automated, and closed monitoring of a set of well-defined CPPs, as indicators of the overall state of the cell culture.

We will select and refine our parameters and establish optimal ranges, as predictors of process outcomes and product quality, based on prediction algorithms and digital twin analysis. This will allow continuous process monitoring while greatly lowering costs and risks associated with manual sampling.

Our first application will be in CAR T cell therapy production, but the advantages of automation with continuous monitoring will be further applied to other CGT products that involve culturing of cells.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 3.617.783
Totale projectbegroting€ 3.617.783

Tijdlijn

Startdatum1-10-2022
Einddatum30-9-2025
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • DA VINCI LABSpenvoerder
  • JOBST TECHNOLOGIES GMBH
  • STEMMATTERS, BIOTECNOLOGIA E MEDICIINA REGENERATIVA SA
  • TECHNISCHE UNIVERSITAET WIEN
  • EXOTHERA SA
  • CROWDHELIX LIMITED
  • LIMULA SA

Land(en)

FranceGermanyPortugalAustriaBelgiumIrelandSwitzerland

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Smart manufacturing for autologous cell therapies enabled by innovative biomonitoring technologies and advanced process control

The SMARTER project aims to develop a smart bioprocessing platform for personalized autologous cell therapies, enhancing manufacturing efficiency and enabling clinical use for solid tumors.

€ 1.364.281
EIC Pathfinder

NOn-VIral gene modified STEM cell therapy

This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.

€ 3.644.418
EIC Pathfinder

AI-powered platform for autologous iPSC manufacturing

The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.

€ 3.999.225
EIC Pathfinder

FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS

T-FITNESS aims to enhance T cell therapy by preventing exhaustion through miRNA-based circuits and CRISPR/Cas editing, improving treatment efficacy for solid tumors in cancer patients.

€ 4.387.825
EIC Pathfinder

Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application

This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.

€ 3.797.562

Vergelijkbare projecten uit andere regelingen

ERC Advanced...

Continuous Digitalized Processes for Producing Biopharmaceuticals

Developing a Digital Twin-based methodology for continuous, integrated biopharmaceutical production to enhance efficiency and support advanced therapies like mRNA vaccines and personalized medicine.

€ 2.500.000
ERC Proof of...

Enabling efficient cell engineering leaving gene-expression BURden OUT for cell therapies and biopharmaceutical industry

BURnOUT is an AI-driven software designed to optimize gene sequences for efficient mammalian cell engineering, aiming to reduce costs and enhance therapies for cancer and biopharmaceuticals.

€ 150.000
ERC Proof of...

Commercial feasibility of a cell-free reactor setup for optimisation of complex enzymatic pathways

This project aims to commercialize a continuous stirred tank reactor for optimizing complex enzymatic pathways, enhancing production efficiency and establishing a viable commercialization strategy.

€ 150.000
ERC Proof of...

Generation, validation and use of a synthetic reporter of CAR T cell products function and dysfunction

Develop a synthetic reporter system to enhance T cell fitness in immunotherapy by identifying and reversing dysfunction in CAR T cells for improved cancer treatment.

€ 150.000
ERC Proof of...

Fast and simple biomarker detection by computational microscopy

We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.

€ 150.000